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A young overweight patient with Mohr–Claussen Syndrome was admitted to our department with the
clinical diagnosis of pulmonary hypertension complaining about dyspnea at rest and excessive daytime
sleepiness. Pulmonary function testing indicated severe airﬂow limitation and respiratory insufﬁciency.
Pulmonary artery (PA) pressure was markedly increased. Pulmonary embolism, Alpha-1-antitrypsin-
deﬁciency, emphysema and anatomical obstructions were excluded. Polysomnography showed recur-
rent oxygen desaturations compatible with alveolar hypoventilations. Hypercapnic ventilatory response
testing (HCVR) indicated a missing increase in minute ventilation when exposed to hypercapnia. After 6
weeks of nocturnal non-invasive ventilation therapy, her clinical condition markedly improved. Further-
more, PA pressure returned to normal values. HCVR testing showed an adequate response to hypercapnia.
Mohr–Claussen syndrome is a rare genetic disease affecting the mouth, face and digits. Adult patients are
usually very obese; exposing them at risk for obesity hypoventilation syndrome (OHS). OHS is described as
a combination of obesity and awake arterial hypercapnia (PaCO2> 45 mmHg) in the absence of other
known causes of chronic alveolar hypoventilation. Unclear pulmonary hypertension in overweight
patients should raise the suspicion for OHS.
 2009 Published by Elsevier Ltd.1. Case presentation
A 32 year-old overweight female patient was admitted to the
department of cardiology with the clinical diagnosis of pulmonary
hypertension.
The patient complained about exercise intolerance, dyspnea at
rest and intractable headache. Two weeks before initial presenta-
tion, her dyspnea progressively worsened and was accompanied by
severe pedal edema. Besides, she mentioned increased daytime
sleepiness (Epworth sleepiness scale (ESS): 18/24) and severe
problems maintaining sleep including recurrent nightmares, which
raised the suspicion for sleep-disordered breathing (Fig. 1).
Her past medical history is signiﬁcant for oro-facial-digital-
syndrome Type II (Mohr Syndrome) which was diagnosed in
childhood. Medications included salbutamol bid, TiotropiumMarburg, Germany, Dept. of
(J.E.S. Nolte), koehleru@med.
A.K. Sohrabi), canisius@med.
ann), claus.vogelmeier@med.bromide qd, an aldosterone antagonist qd (25 mg/day) and furo-
semide qd (20 mg/day). She smokes half a pack of cigarettes per day
and has done so for the previous 12 years.
At time of admission, her height was 148 cmwith a body weight
of 95 kg, corresponding to a body-mass index of 44 kg/m2. Blood
pressure was 140/85 mmHg, heart rate 90 beats per minute. Aside
from her obesity, nodules of the tongue, polydactyly, midline cleft
of the lip, cyanosis of her hands as well as ankle edema were
observed during physical examination. Both lungs were clear on
auscultation; the remainder of the physical exam revealed no
additional signiﬁcant ﬁndings.
Blood gas analysis showed a carbon dioxide pressure of
63.2 mmHg, an oxygen partial pressure of 38.3 mmHg and an
oxygen saturation at room air of 77%, compatible with respiratory
insufﬁciency. Pulmonary function testing (PFT) indicated severe
airﬂow limitation (FEV1: 28% predicted, FEV1/FVC ratio: 48% pre-
dicted, airway resistance R: 281% predicted) and hyperinﬂation
(residual volume 193% predicted). Furthermore, diffusion capacity
of the lungs was impaired (transfer factor for carbon monoxide
(DLCO): 62% predicted).
Signiﬁcant ﬁndings in the blood were a sodium level of
124 mEq, a potassium level of 2.9 mEq and a C-reactive protein of
28 mg/dl. Alpha-1-antitrypsin level was within normal range.
Fig. 1. Oxygen saturation and heart rate during seven hours of sleep.
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enlargement of the right and left ventricle and the right atrium.
Cardiac ultrasound revealed a massively dilated right atrium and
ventricle. The estimated systolic pulmonary artery pressure was
83 mmHg. A subsequently performed right heart catheterisation
conﬁrmed a systolic pulmonary arterial pressure of 82 mmHg, a
diastolic pressure of 36 mmHg and a mean pressure of 51 mmHg.
The mean pulmocapillary wedge pressure (PCWP) was 18 mmHg.
Polysomnography showed recurrent oxygen desaturations down
to 48% compatible with alveolar hypoventilations without any signs
of obstructive or central sleep-disordered breathing (Fig. 1).
Pulmonary embolismwas excluded by a spiral chest CAT scan. In
High-Resolution CT (HRCT) scan, no signs of parenchymal damage,
emphysema or anatomical obstructions were found.
Hypercapnic ventilatory response (HCVR) testing was initiated
(Fig. 2, label ‘day1’), showing a very shallow rise in her minute
ventilation when exposed to increasing levels of carbon dioxide.
Testing was stopped when endexpiratory carbon dioxide values
exceeded 100 mmHg.
The patient was subsequently treated with nocturnal nasal
continuous positive bilevel (nBiPAP) ventilation (ventilator
settings: inspiratory positive airway pressure: 19 cm H2O, expira-
tory pressure: 10 cm H2O, spontaneous/timed mode (‘‘ST’’), respi-
ratory rate: 15/min).
She returned 4 weeks later for follow-up. Her general clinical
condition had improved markedly, she was able to walk two ﬂights
of stairs without any signs of dyspnea; her sleeping problems had
vanished (ESS: 4/24). HCVR testing was repeated (Fig. 2, label
‘day30’), now illustrating a sharp rise in minute ventilation. Testing
was stopped by the patient because of dyspnea.
During a second follow-up 8weeks after treatment initiation, her
pulmonary artery pressure was measured again using ultrasoundFig. 2. The hypercapnic ventilatory response (HCVR) on three different occasions.yielding a complete resolution of her PH with an estimated mean
systolic pressure of 12 mmHg. The HCVR (Fig. 2, label ‘day60’)
showed a parallel line as compared to day 30,with a further left shift
to normocapnic values. Moreover, we were able to stop her diuretic
medications.
2. Discussion
Mohr–Claussen syndrome or oro-facial-digital-syndrome type II
is a rare autosomal recessive genetic disease characterised by
tongue lobulation, midline cleft lip, high arched or cleft palate,
broad nasal root with wide biﬁd nasal tip, hypertelorism, micro-
gnathia, brachydactyly, syndactyly and polydactyly, bilateral redu-
plicated hallux, conductive hearing loss and normal intelligence.1
We suggest that pulmonary complications may be part of Mohr
Syndrome. Our suspicion is supported by the fact that the patient’s
27 year-old sister who suffers from the same genetic disease was
admitted to our department 6 weeks later. PFT showed similar
changes as in her sister’s case with severe airway obstruction,
hyperinﬂation and respiratory insufﬁciency.
Adult patientswithMohr’s Syndrome share featureswithObesity
Hypoventilation Syndrome (OHS), including obesity. OHS is
described as a combinationof obesity and awake arterial hypercapnia
(PaCO2> 45 mmHg) in the absence of other known causes of chronic
alveolar hypoventilation.2 OHS is thought to be the consequence of
increased work of breathing due to obesity, normal or diminished
respiratory drive, other associated sleep related breathing disorders
such as obstructive sleep apnea, as well as endocrinological alter-
ations like increased leptin resistance.3 These patients commonly
experience a reduced electromyographic neuromuscular and venti-
latory response to hypercapnia.4 Non-invasive mechanical ventila-
tion (NIMV) can effectively improve clinical symptoms and daytime
respiratory failure and can enhance the responsiveness to carbon
dioxide. It has been suggested that an increase in leptin levels may
reverse the blunted responsiveness to CO2 in OHS patients during
NIMV.5,6
Another signiﬁcant ﬁnding is the association between OHS and
pulmonary hypertension (PH): In a large French trial investigating
patients with OHS, more than 50% of these had PH, a much higher
percentage than the 9% observed in patients with obstructive sleep
apnea.7
Pulmonary hypertension is deﬁned as a mean pulmonary artery
pressure greater than 25 mmHg at rest or 30 mmHg with exercise.8
According to the Dana Point classiﬁcation from 2008, PH is divided
into six subgroups, namely pulmonary artery hypertension,
pulmonary veno-occlusive diseases and/or pulmonary capillary
hemangiomatosis, PH owing to left heart disease, PH owing to lung
diseases and/or hypoxia (including OHS), chronic thromboembolic
PH, and PH with unclear multifactorial mechanisms.9 The complex
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vasoconstriction, endothelial cell proliferation and thrombosis.10
PH in patients with OHS may be either caused by chronic left
heart failure following left ventricular hypertrophy (which is
a common ﬁnding in severe obesity) or directly by alveolar
hypoxia.11
To date, there is no reported data regarding the alterations in PH
after initiation of NIMV in OHS patients.
We are aware that the PH in our patient may also be secondary
to her obstructive lung pattern. Nevertheless, it would be very
unlikely that this form of PH would respond to NIMV. Moreover,
PFT in morbid obese patients usually shows a restrictive pattern
owing to increased chest wall impedance.
The Hypercapnic Ventilatory Response (HCVR) testing was
performed using a modiﬁed Read rebreathing device. Our setup
adjusts automatically the fractions of oxygen, carbon dioxide and
nitrogen in a closed loop system. The distinct changes in herminute
ventilation when exposed to increasing levels of carbon dioxide
with a sharp increase within 60 days of NIMV show impressively
the dynamic properties of pulmonary chemoreceptors maintaining
their full potential for recovery over a long time.
Unclear pulmonary hypertension in overweight patients should
raise the suspicion for obesity hypoventilation syndrome, particu-
larly because early recognition and treatment improves outcome.
We emphasize the importance of arterial blood gas testing in these
patients to evaluate fordaytimehypercapnia. Additionally, nocturnaltranscutaneous capnography may be a helpful tool establishing
a diagnosis.
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